PTC Therapeutics Inc

PTCT

Equity

ISIN US69366J2006 / Valor 2515234

NASDAQ (2024-09-17)

USD 35.07+3.85%

PTC Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

PTC Therapeutics Inc is an established global biopharmaceutical company focused on delivering transformative therapies for individuals with rare diseases. With a history spanning 25 years, the company utilizes scientific platforms to develop new treatments that target the root cause of the disease. PTC Therapeutics Inc is dedicated to providing innovative solutions that improve the quality of life for those who rely on their therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue

PTC Therapeutics Inc. reported total revenues of $186.7 million for the second quarter of 2024, a decrease from $213.8 million in the same quarter of 2023. This decline was primarily due to lower net product revenue across their commercial portfolio.

Net Product Revenue

Net product revenue for PTC Therapeutics Inc. in the second quarter of 2024 was $133.2 million, compared to $174.6 million in the second quarter of 2023. The decrease was influenced by the timing of bulk government orders for Translarna and the expiration of Emflaza's orphan drug exclusivity.

Royalty Revenue

PTC Therapeutics Inc. saw an increase in royalty revenue, reporting $53.2 million for the second quarter of 2024, up from $36.9 million in the same period of 2023. This increase was driven by higher sales of Evrysdi, which resulted in increased royalty payments to PTC.

Research and Development Expenses

GAAP research and development (R&D) expenses for PTC Therapeutics Inc. were $132.2 million in the second quarter of 2024, down from $185.9 million in the second quarter of 2023. This reduction reflects strategic portfolio prioritization and a focus on high-potential programs.

Net Loss

PTC Therapeutics Inc. reported a net loss of $99.2 million for the second quarter of 2024, an improvement from the net loss of $198.9 million in the same quarter of 2023. The reduction in net loss was attributed to lower operating expenses and strategic financial management.

Summarized from source with an LLMView Source

Key figures

33.5%1Y

-17.7%3Y

-19.0%5Y

Performance

73.2%1Y

59.1%3Y

55.6%5Y

Volatility